All posts by: admin

NIH to Showcase Imbed Bio in Innovation Zone at BIO 2016 in San Francisco, CA

Madison, WI (May 1, 2016)- Imbed Bio announces that it will exhibit at the 2016 Biotechnology Industry Organization (BIO) International Convention in San Francisco, CA from June 6-9, 2016. National Institutes of Health has selected to showcase Imbed Bio as one of its 50 top funded technologies. Imbed will host a kiosk in the Innovation Zone, an area of the exhibition floor that is dedicated to showcasing Small Business Innovation Research (SBIR) grantees.

SBIR grants provide early-stage funding for small businesses, and Imbed Bio currently has a $1.5M SBIR grant from the NIH to develop antimicrobial microfilm dressing with ionic and metallic silver for management of chronic wounds. Ankit Agarwal, PhD (CEO) will attend the convention and introduce company’s technology platform and pipeline products to potential customers, corporate partners and investors. Please contact Ankit Agarwal through the One-on-One Partnering System at the BIO Conference website if you would like to schedule a meeting at BIO 2016.

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company, located in Madison, WI. Imbed’s vision is to develop next-generation medical devices that can reduce patient pain and costs for management of burns, chronic wounds, hernia meshes, gastro-intestinal defects, and dural membranes. Company has a portfolio of products in development based on its synthetic and biodegradable thin films platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and promote wound healing. For more information, please visit www.imbedbio.com.

Dow Chemist Joins Imbed Biosciences Team

Madison, WI, (December 1, 2014) – Imbed Biosciences, a developer of advanced biomaterials for surgical and wound care, announced today that Gaurav Pranami, Ph.D. will join the Imbed Biosciences team as Director of Research & Development. Dr. Pranami will head expansion of Imbed’s bioactive polymeric microfilm technology and its transfer into scalable manufacturing processes. He brings 11 years of chemical and computational research experience to Imbed. He worked as senior engineer at Dow Chemical Company for the past 5 years on innovative inks, functional paper coatings, adhesives, textiles and non-wovens. Gaurav received his BS from the Indian Institute of Technology, Delhi, and his Ph.D. in Chemical Engineering from Iowa State University, Ames, IA, and did his post-doctoral research at University of Wisconsin-Madison.

“I have known Gaurav for several years and I am delighted that he is joining Imbed to lead research and development of microfilm technology,” said Ankit Agarwal, President and CEO of Imbed. “His prior experience will help accelerate Imbed’s technical progress toward bringing our microfilm wound contact film dressings to market.”

“I have been closely monitoring Imbed’s progress for the past few years. I am excited for this opportunity to join the team and help bring the company’s exciting wound care technology to market,” said Pranami.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow @imbedbio on twitter.

Madison, Wisconsin (September 11, 2014) – Strategic operating capital fund, Wisconsin Investment and Strategic Capital Partners (“WISC Partners”), has made the lead investment in Imbed Biosciences (“IMBED”) in order to advance the development and commercialization of their promising wound healing technology.

WISC Partners LP is a strategic operating capital fund that invests not just capital, but also provides expertise in company building, in business development, and in delivering liquidity events to its selected ventures. Comprised of University of Wisconsin alumni who have built their careers in Silicon Valley, the firm is committed to building wealth for both investors and entrepreneurs in the state of Wisconsin.

“We achieved everything we set out to do in our fund raising process and more”, says Ankit Agarwal, CEO and cofounder of IMBED. “WISC Partners has helped us to identify and now pursue additional applications and opportunities for our wound healing technology. We have already gained far more value than funding alone from our work together. This is a tremendous partnership for us.”

In addition to the investment by WISC Partners, IMBED has also been recently awarded with $1.5 million in funding from the National Institute of Health to further the testing of its unique polymeric nanofilm technology, which is designed for wound healing and surgical applications.

According to David Guinther, a General Partner at WISC Partners, “IMBED has everything that we look for in an investment: a strong team of founders, impressive progress to date, a clear product-market fit, and a product with the potential to become a platform with broad applications. We are very pleased to be working with the remarkable team at IMBED.”

Adds Sanjeev Chitre, also a General Partner at WISC Partners and who is joining the Board of Directors of IMBED, “This technology has the potential to address a wide range of challenges in advanced wound care, and we see additional opportunities within the military, in the veterinarian market, and in international markets. The identification and effective pursuit of these opportunities is part of the value that WISC Partners brings to IMBED.”

About WISC Partners

Our mission at WISC Partners is to create wealth by helping a portfolio of well-chosen entrepreneurs in Wisconsin to build great companies that solve important customer problems. We accomplish this by injecting Strategic Operating Capital into these investments, which couples funding with company building experience, product and market expertise, corporate and business development networks, and highly engaged executive support. We are comprised of University of Wisconsin alumni, with offices in Madison, WI and Milpitas, CA.For more information, please visit www.wiscpartners.com.

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company, located in Madison, WI, that develops advanced materials for wound healing and surgical applications. It has developed polymeric nanofilms and microfilms for delivering tailored loadings of bioactive molecules on tissue surfaces. Its vision is to develop next-generation surgical devices that can reduce patient pain and overall treatment costs, including antimicrobial dressings for dermal wounds, hernia surgical meshes, barrier films for gastro-intestinal defects, and dural membranes. The company’s first family of products targets the antimicrobial wound dressings market. For more information, please visit www.imbedbio.com.

Madison, WI (July 28, 2014)– Imbed Biosciences, Inc, a medical device company developing advanced materials for wound healing and surgical applications, announced today that it has been awarded a $1.5M competitive Small Business Innovation Research (SBIR) Phase II grant from National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of National Institutes of Health (NIH).

“It a very competitive award, which validates the uniqueness of this polymeric nanofilm technology. A significant merit is that the concept is adaptable to delivery of a wide range of bioactive molecules on tissue surfaces, providing a broadly applicable healthcare materials platform”, said co-founder Nicholas Abbott, PhD, Professor in Department of Chemical and Biological Engineering at University of Wisconsin-Madison.

“This next-generation wound dressing will be applicable at the onset of any wound treatment plan without silver toxicity. The nanofilm dressing dissolves in wound over time, potentially reducing painful dressing changes”, said co-founder Prof. Michael Schurr, MD, burn and trauma surgeon in School of Medicine at University of Colorado, Denver.

With this funding, Imbed plans to begin testing the nanofilm dressing in pigs. “Clinical data from porcine wounds will be used to obtain regulatory clearance for human clinical trials”, said co-founder Prof. Jonathan McAnulty, DVM, PhD, leading porcine studies as a part of this grant in School of Veterinary Medicine at University of Wisconsin-Madison.

“Wound healing research is an important component of the NIAMS portfolio. It is part of an effort to reduce the impact of human skin wounds on public health and the economy. This SBIR Phase II award to Imbed Bio reflects our commitment to meet this public need,” said Dr. Hung Tseng, Program Director of the Skin Repair, Regeneration and Pigmentation Program in the Division of Skin and Rheumatic Diseases at the NIAMS.

“We have a team of renowned experts in surface engineering, microbiology and surgical sciences committed to bring this wound healing nanofilm technology into clinics”, said Agarwal.

About Imbed Biosciences:

Imbed Biosciences Inc. is a privately held medical device company located in Madison, WI. Company has patent-pending technologies on polymeric nanofilms and microfilms for delivering tailored loadings of bioactive molecules on tissue surfaces. Company’s vision is to develop next-generation surgical devices that can reduce patient pain and overall treatment costs, including antimicrobial dressings for dermal wounds, hernia surgical meshes, barrier films for gastro-intestinal defects, and dural membranes. For more information, visit http://www.imbedbio.com.

Madison, WI (Jan 1, 2014)– Imbed Biosciences, Inc. announced today that it has been awarded a $150K competitive Small Business Innovation Research (SBIR) Phase I grant from National Science Foundation (NSF). During the 6-month project titled, “Antimicrobial and antibiofilm microfilm wound dressings”, the company will develop micrometer-thick polymeric wound dressings that contain antibiofilm agent gallium and antimicrobial agent silver, and investigate their synergistic effect against microbial proliferation.

Ankit Agarwal, PhD, Founder/CEO of Imbed and the Principal Investigator on the grant, said, “we are very excited to receive this NSF award as validation of our innovative technology to develop unique antibiofilm wound dressings and the market demand for improved formulations to prevent wound infections in burns and chronic ulcers. These funds will support our ongoing investment in company’s patent-pending technology and personnel to bring unique microfilm wound dressings into clinics”.

The company is collaborating with Prof. Charles J. Czuprysnki, PhD in the Department of Pathobiology at School of Veterinary Medicine, University of Wisconsin-Madison. Antimicrobial experiments will be conducted in BSL-2 certified laboratories of Prof. Czuprynski as part of a subcontract under this award.

Successful completion of this Phase 1 project will provide microfilm dressings suitable for tests in porcine wounds in Phase II, required for regulatory clearance for their use in human patients. “Emerging fundamental concepts of managing wound surface infections would be generalizable to various clinical procedures where microbial colonization is a serious problem, such as hernia surgeries or gastro-intestinal defects, promising a broad clinical, social and economic impact”, said Agarwal.

About Imbed Biosciences:

Imbed Biosciences Inc. is a privately held medical device company located in Madison, WI, developing advanced materials for wound healing and surgical applications. Company has patent-pending technologies on polymeric nanofilms and microfilms for delivering tailored loadings bioactive molecules on tissue surfaces. Company’s vision is to develop next-generation surgical devices that can reduce patient pain and overall treatment costs, including antimicrobial dressings for dermal wounds, hernia surgical meshes, barrier films for gastro-intestinal defects, and dural membranes. Company’s first family of products is targeted for the $1.5B global antimicrobial wound dressings market. For more information, visit http://www.imbedbio.com.

Madison, WI (April 13, 2012)– Imbed Biosciences, Inc., a privately held medical device company developing novel advanced materials for wound healing and surgical applications, announced today that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant in the amount of $326,489 by the National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the National Institutes of Health (NIH).During the twelve-month project, titled “Antibacterial molecular coatings pre-fabricated for biologic wound dressings”, Imbed will collaborate with Dr. Jonathan F. McAnulty, DVM, PhD, Professor and Chair of Surgical Sciences in the School of Veterinary Medicine at the University of Wisconsin-Madison.

“This award provides important validation and support for our technology to develop next-generation wound dressings for surgical and chronic wounds. It will facilitate our ongoing investment in personnel and research,” said Ankit Agarwal, PhD, President and CEO of Imbed, and the principal investigator on the grant. “We are also extremely excited to collaborate with Dr. McAnulty, a leading researcher and surgeon at one of the world’s premier institutes of veterinary science”.

“Antibacterial nanofilms being developed by Imbed will modify the surfaces of biologic dressings to actively prevent wound infections and promote cellular growth and healing,” said Dr. McAnulty. “I am thrilled to be collaborating with Dr. Agarwal and other researchers at Imbed in investigating the safety and efficacy of these nanofilms in small-animal wound models”.

“Currently availablebiologic dressings expedite closure of hard-to-heal burns and chronic wounds, but are also associated with a high incidence of wound infections. Imbed’s technology presents the promise to deliver antibacterial biologic dressings desired by clinicians,” said Dr. Michael J. Schurr, MD, a burn and trauma injury surgeon and Professor in the School of Medicine at the University of Colorado, Denver, and a member of Imbed’s Scientific Advisory Board.

The following researchers will also formally collaborate on the project with Imbed as members of the Company’s Scientific Advisory Board:

-Nicholas L. Abbott, PhD, Professor and Chairman, Department of Chemical and Biological Engineering, University of Wisconsin-Madison

-Charles J. Czuprynski, PhD, Professor, School of Veterinary Medicine, University of Wisconsin-Madison

Imbed Biosciences, Inc, headquartered in Madison, WI, is a privately held medical device company developing novel and patent-pending technologies for imbedding bioactive agents in wound dressings and surgical implants. By leveraging its novel nanofilms platform, Imbed is revolutionizing biologic dressings to prevent wound infections and expedite wound closure, and ideally reduce the overall cost of managing surgical and chronic wounds, which constitutes a $3 billion market opportunity in the U.S. For more information, visit http://www.imbedbio.com